Positive Findings, Collaborations, and NDA Filings Strengthen Pipelines - Research Report on Clovis Oncology, MannKind, TESARO,

  Positive Findings, Collaborations, and NDA Filings Strengthen Pipelines -
       Research Report on Clovis Oncology, MannKind, TESARO, Peregrine
                  Pharmaceuticals, and Vanda Pharmaceuticals

PR Newswire

NEW YORK, June 6, 2013

NEW YORK, June 6, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Wall Street Reports announced new research reports highlighting Clovis
Oncology Inc. (NASDAQ: CLVS), MannKind Corporation (NASDAQ: MNKD), TESARO Inc.
(NASDAQ: TSRO), Peregrine Pharmaceuticals (NASDAQ: PPHM), and Vanda
Pharmaceuticals Inc. (NASDAQ: VNDA). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Clovis Oncology Inc. Research Report

On June 3, 2013, Clovis Oncology Inc. (Clovis Oncology) announced initial
findings from the Phase I portion of its ongoing Phase I/II clinical study of
CO-1686, the novel, oral, targeted covalent (irreversible) inhibitor of mutant
forms of the epidermal growth factor receptor (EGFR) for the treatment of
non-small cell lung cancer (NSCLC) in patients with initial activating EGFR
mutations as well as the dominant resistance mutation T790M. According to the
Company, three of four evaluable T790M patients treated at 900mg BID
(twice-daily) achieved partial responses. Further, it reported that CO-1686
appeared well-tolerated, with no evidence of wild-type EGFR inhibition. Dr.
Lecia V. Sequist of the Massachusetts General Hospital Cancer Center and
Associate Professor of Medicine at Harvard Medical School, Boston, said, "It
has been exciting and quite hopeful to observe that patients are responding to
CO-1686 and that the side effect profile has been so mild. A drug that works
effectively for EGFR acquired resistance would be welcomed by the lung cancer
community." The Full Research Report on Clovis Oncology Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.wsreports.com/r/full_research_report/6b27_CLVS]

--

MannKind Corporation Research Report

On May 31, 2013, MannKind Corporation (MannKind) announced that all follow-up
visits have been completed for patients enrolled in Study 171, a Phase 3
clinical study of AFREZZA (insulin human [rDNA origin]) inhalation powder, an
investigational, ultra rapid-acting mealtime insulin therapy, administered
using the Company's next-generation inhaler. Study 171 is an open-label study
in patients with type 1 diabetes. After a run-in period, during which all
patients were optimized on their basal insulin regimen, 518 subjects were
randomized to one of three arms for mealtime insulin: a control arm, in which
patients utilize rapid-acting insulin, or one of two AFREZZA arms, one for the
MedTone inhaler and the other for the next-generation inhaler. After the
mealtime insulin was titrated, there was a 12-week observation period on
stable doses of the mealtime insulin to assess HbA1c levels, which is the
primary outcome parameter. The Company expects to release data from this study
in the summer of 2013. The Full Research Report on MannKind Corporation -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/0b44_MNKD]

--

TESARO Inc. Research Report

On June 3, 2013, TESARO, Inc. (TESARO), Breast International Group (BIG), a
non-profit organization for academic breast cancer research groups from around
the world, and the European Organization for Research and Treatment of Cancer
(EORTC), an international, independent, multidisciplinary non-profit research
organization, announced a partnership for the Phase 3 clinical development of
niraparib, an orally active, potent poly (ADP-ribose) polymerase (PARP)
inhibitor. TESARO, BIG and EORTC will use BIG's and EORTC's scientific and
clinical expertise and network of collaborative groups and their associated
hospitals and oncology research centers to accelerate the completion of the
Phase 3 clinical trial of niraparib in patients with breast cancer. The
primary endpoint of this trial is progression free survival (PFS), with
overall survival (OS) as a secondary endpoint. TESARO expects to open this
study to patients during the second half of 2013. The Full Research Report on
TESARO Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/4f59_TSRO]

--

Peregrine Pharmaceuticals Research Report

On June 3, 2013, Peregrine Pharmaceuticals, Inc. (Peregrine Pharmaceuticals)
reported that data was presented at the 2013 ASCO (American Society of
Clinical Oncology) Meeting from two clinical trials evaluating the Company's
lead clinical candidate bavituximab, a first-in-class phosphatidylserine
(PS)-targeting monoclonal antibody that represents a new approach to treating
cancer. Interim data from a Phase I trial, evaluating bavituximab plus
paclitaxel therapy in patients with HER2-negative metastatic breast cancer
(MBC), showed that 85% of patients were able to achieve objective tumor
response, with 15% of patients achieving a complete response (CR) in
accordance to Response Evaluation Criteria in Solid Tumors (RECIST). Further,
the Company reported that in the second study, results from a randomized Phase
II trial of bavituximab plus gemcitabine in patients with non-resectable Stage
IV pancreatic cancer demonstrated more than a doubling of the overall response
rate (ORR) and an improvement in overall survival (OS), including a delayed
separation in the Kaplan-Maeier survival curve that is commonly seen in
promising cancer immunotherapies. The Full Research Report on Peregrine
Pharmaceuticals - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/df4a_PPHM]

--

Vanda Pharmaceuticals Inc. Research Report

On May 31, 2013, Vanda Pharmaceuticals Inc. (Vanda Pharmaceuticals) announced
the submission of a New Drug Application (NDA) to the U.S. Food and Drug
Administration (FDA) for tasimelteon, a circadian regulator in development for
the treatment of non-24 hour disorder (Non-24) in the totally blind. Non-24 is
a serious and rare, circadian rhythm disorder that affects the majority of
totally blind individuals who lack light perception and, therefore, cannot
synchronize their master body clock to the 24-hour day. There are currently no
FDA approved products for the treatment of Non-24. The Full Research Report on
Vanda Pharmaceuticals Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/b7a8_VNDA]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquires, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Wall Street Reports

Contact: WSReports.com Phone #: +1-310-496-8071 (North America)